Parallel Advisors’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Parallel Advisors’s Portfolio KRTX Stock Details KRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-238	Closed	-$75.3K	–	3450
2023 Q4	$75.3K	Buy	238 +45	+23%	+$8.75K	﹤0.01%	1244
2023 Q3	$32.6K	Hold	193	–	–	﹤0.01%	1608
2023 Q2	$41.9K	Buy	193 +4	+2%	+$857	﹤0.01%	1489
2023 Q1	$34.3K	Sell	189 -3	-2%	-$574	﹤0.01%	1567
2022 Q4	$37.7K	Buy	192 +170	+773%	+$36.5K	﹤0.01%	1406
2022 Q3	$5K	Buy	22 +3	+16%	+$607	﹤0.01%	2344
2022 Q2	$2K	Buy	+19	New	+$2.18K	﹤0.01%	2672
2022 Q1	–	Sell	-1	Closed	–	–	3360
2021 Q4	$0	Buy	+1	New	+$129	﹤0.01%	3359
2020 Q4	–	Sell	-4,965	Closed	-$384K	–	2767
2020 Q3	$384K	Hold	4,965	–	–	0.02%	363
2020 Q2	$553K	Buy	+4,965	New	+$432K	0.04%	274

Other funds holding KRTX

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

Parallel Advisors's KRTX Position: Q1 2024 in Review

Parallel Advisors sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 238 shares — an estimated $75.3K sold.

Parallel Advisors first reported a position in KRTX in Q2 2020 and held it in 10 quarters. The position peaked at $553K in Q2 2020. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.

Parallel Advisors reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Parallel Advisors sold 238 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $75.3K.
Parallel Advisors first reported a position in Karuna Therapeutics, Inc. Common Stock in Q2 2020 and held it in 10 quarters.
Parallel Advisors's Karuna Therapeutics, Inc. Common Stock position peaked at $553K in Q2 2020.
2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Parallel Advisors's 13F filing for Q1 2024, filed 6 May 2024.